SIRT With Tremelimumab and Durvalumab for Resectable HCC

NCT05701488 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Hepatocellular Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DEVICE: SIRT

Sponsor

Jiping Wang, MD, PhD

Collaborators

[object Object]
[object Object]